BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKE
(Financial Post, 2025-12-18T11:07:56Z)